RT Journal Article
SR Electronic
T1 Expression profiles of circRNAs and identification of hsa_circ_0007608 and hsa_circ_0064656 as potential biomarkers for COPD-PH patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.04.16.23288654
DO 10.1101/2023.04.16.23288654
A1 Yu, Jinyan
A1 Huang, Shulun
A1 Shen, Weiyu
A1 Zhang, Zheming
A1 Ye, Shugao
A1 Chen, Yuan
A1 Yang, Yue
A1 Bian, Tao
A1 Wu, Yan
YR 2023
UL http://medrxiv.org/content/early/2023/04/24/2023.04.16.23288654.abstract
AB Pulmonary hypertension(PH) is a common complication of chronic obstructive pulmonary disease(COPD) which can worsen the prognosis and increase the mortality of COPD patients. However, the underlying mechanisms of PH in COPD(COPD-PH) remain to be elucidated. This study is the first to explore the expression profile of circRNAs in human lung tissues with definite diagnosis of COPD-PH and validate the differentially expressed circRNAs(DECs) utilizing human serum, pulmonary arterial endothelial cells(HPAECs) and pulmonary arterial smooth muscle cells(HPASMCs). A total of 136 circRNAs(39 up-regulated and 97 down-regulated) were differentially expressed between the COPD-PH group and the control group. Following quantitative real-time polymerase chain reaction(qRT-PCR) validation, two circRNAs (hsa_circ_0007608 and hsa_circ_0064656) were believed to be involved in the pathogenesis. GO and KEGG pathway analysis suggested these two DECs were mainly related to the celluar proliferation, migration and EndoMT. PPI network revealed 11 pairs of key mRNAs. VCAM1, VCAN and THBS1, three hub mRNAs with the highest reliability among all, were validated and proven to be up-regulated in COPD-PH. We innovatively found that VCAN may be involved in COPD-PH. These identified genes show high potential to be diagnostic markers and therapeutic targets of COPD-PH, and may provide new insights into the underlying mechanisms of COPD-PH patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Natural Science Foundations of China (82173472), the Top Talent Support Program for young and middle-aged people of Wuxi Health Committee (BJ2020006) and General Program of Wuxi Health Committee(M202032).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:the ethical review board of Wuxi People’s Hospital Affiliated to Nanjing Medical UniversityI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll relevant data are within the manuscript and its Supporting Information files. https://www.ncbi.nlm.nih.gov/sra/PRJNA913650